Fighting COVID-19 effectively

Worldwide research and collaboration needed to combat the coronavirus, says GlobalData
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LONDON—In light of the recent novel coronavirus outbreak (COVID-19), data and analytics company GlobalData has analyzed several of the largest COVID-19 clinical trials in terms of participant size, with one the company’s clinical trials analysts, Mohamed Abukar, noting, “GDCT0379047 (ChiCTR2000029573) and GDCT0379500 (ChiCTR2000029602) are the two largest coronavirus trials, with both trials aiming to recruit 600 participants.”
 
Trial GDCT0379047, an interventional planned Phase 4 trial, tests the efficacy and safety of a recombinant cytokine gene-derived protein injection combined with umifenovir (Arbidol), lopinavir/litonavir. The study aims to combine the immunostimulatory effects of the cytokine gene-derived protein injection with the anti-viral properties of umifenovir, lopinavir/litonavir against COVID-19. This trial is located in Zhejiang, China, and is sponsored by the Zhejiang University School of Medicine Hospital 1 in collaboration with Jiehua Biotechnology (Qingdao) Co.
 
Trial GDCT0379500, an interventional ongoing Phase 0 study, aims to test the preventative effects of traditional Chinese medicine (TCM) against COVID-19. This study aims to determine if the addition of TCM to standard health education is more effective than health education alone in preventing COVID-19. This trial is located in Hubei, China, and is sponsored by the Hubei Hospital of Traditional Chinese Medicine in collaboration with the State Administration of Traditional Chinese Medicine.
 
Concluded Abukar: “Evidently, a substantial research effort has been geared toward therapies utilizing umifenovir or TCM, with four of the top five clinical trials involving these agents. Nevertheless, to effectively combat the disease, a greater level [of] research and collaboration is required worldwide; currently an overwhelming amount of the research is being conducted in China, which may limit the scope of potential therapies being investigated.”

Related Topics

Published In

Volume 16 - Issue 3 | March 2020

March 2020

March 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue